Employing advanced left atrial automated functional myocardial imaging technology to investigate whether patients with lupus nephritis (LN) experience more severe cardiac impairment compared to extra-renal systemic lupus erythematosus (extra-renal SLE) patients, while also identifying the primary risk factors affecting left atrial reservoir strain (LASR) in LN patients.
Methods
Routine echocardiographic evaluations were performed on patients with lupus nephritis (LN), Extra-renal systemic lupus erythematosus (SLE), and healthy controls. The left atrial automated functional imaging (AFILA) technique was employed to measure LASR, left atrial conduit strain (LASCD), and left atrial contraction strain (LASCT) for all study participants. Demographic characteristics of all participants were collected, along with clinical and laboratory features for the case group.
Results
We included 42 healthy controls, 91 patients with extra-renal SLE, and 79 patients with LN. LASR, LASCD, and LASCT in the LN group were all significantly lower than those in the extra-renal SLE group and the control group, with the extra-renal SLE group also exhibiting lower values than the control group (LASR: 22.00% vs 27.00% vs 36.00%, p < .001; LASCD: −14.00% vs −17.00% vs −24.00%, p < .001; LASCT: −9.00% vs −10.00% vs −14.00%, p < .001). A multiple regression analysis of LASR in the LN group indicated that triglycerides (TG) were the sole laboratory indicator independently associated with it (β[SE]: −1.025 [0.370], p = .007).
Conclusions
The degree of LA involvement in patients with LN was significantly greater than in those with extra-renal SLE, with TG potentially serving as the only laboratory indicator capable of effectively predicting LASR. Furthermore, AFILA technology demonstrates considerable potential for the early identification of subclinical myocardial damage.
AndersH-JSaxenaRZhaoM-H, et al.Lupus nephritis. Nat Rev Dis Primers2020; 6: 7.
2.
ArnaudLTektonidouMG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology2020; 59: v29–v38.
3.
EmaraMHafezMAEl-BendaryA, et al.Speckle tracking echocardiography for the evaluation of left ventricular function in children with systemic lupus erythematosus. Lupus2020; 29: 1449–1455.
4.
OliveiraCBKaplanMJ. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol2022; 44: 309–324.
5.
YazdanyJPooleyNLanghamJ, et al.Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open2020; 6: e001247.
6.
YafasovaAFosbølELSchouM, et al.Long-term cardiovascular outcomes in systemic lupus erythematosus. J Am Coll Cardiol2021; 77: 1717–1727.
7.
HermansenM-LLindhardsenJTorp-PedersenC, et al.The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study. Rheumatology2017; 56: 709–715.
8.
JainVGhoshRGuptaM, et al.Contemporary narrative review on left atrial strain mechanics in echocardiography: cardiomyopathy, valvular heart disease and beyond. Cardiovasc Diagn Ther2021; 11: 924–938.
9.
ThomasLMuraruDPopescuBA, et al.Evaluation of left atrial size and function: relevance for clinical practice. J Am Soc Echocardiogr2020; 33: 934–952.
10.
RaafsAGVosJLHenkensMTHM, et al.Left atrial strain has superior prognostic value to ventricular function and delayed-enhancement in dilated cardiomyopathy. JACC Cardiovasc Imaging2022; 15: 1015–1026.
11.
PiñaPLorenzattiDPellikkaPA, et al.Prognostic value of left atrial strain in multiple myeloma. Eur J Intern Med2023; 114: 150–153.
12.
CohenJ. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988.
13.
AringerMCostenbaderKDaikhD, et al.2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis2019; 78: 1151–1159.
14.
MitchellCRahkoPSBlauwetLA, et al.Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography. J Am Soc Echocardiogr2019; 32: 1–64.
15.
NaguehSFKhanSU. Left atrial strain for assessment of Left Ventricular diastolic function: focus on populations with normal LVEF. JACC Cardiovasc Imaging2023; 16: 691–707.
16.
HoiAIgelTMokCC, et al.Systemic lupus erythematosus. Lancet2024; 403: 2326–2338.
17.
PsychariSNApostolouTSSinosL, et al.Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol2005; 95: 764–767.
18.
RaoAKDjamaliAKorcarzCE, et al.Left atrial volume is associated with inflammation and atherosclerosis in patients with kidney disease. Echocardiography2007; 25: 264–269.
19.
KimKKSheppardDChapmanHA. TGF-β1 signaling and tissue fibrosis. Cold Spring Harbor Perspect Biol2018; 10: a022293.
20.
VlachopoulosCAznaouridisKStefanadisC. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol2010; 55: 1318–1327.
21.
PengFPanHWangB, et al.The impact of angiotensin receptor blockers on arterial stiffness: a meta-analysis. Hypertens Res2015; 38: 613–620.
22.
JiaGAroorARHillMA, et al.Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension2018; 72: 537–548.
23.
Kusche-VihrogKJegglePOberleithnerH. The role of ENaC in vascular endothelium. Pflugers Arch2013; 466: 851–859.
24.
ZengYWatersMAndrewsA, et al.Fluid shear stress induces the clustering of heparan sulfate via mobility of glypican-1 in lipid rafts. Am J Physiol Heart Circ Physiol2013; 305: H811–H820.
25.
ParichatikanondWDuangratRMangmoolS. Gαq protein-biased ligand of angiotensin II type 1 receptor mediates myofibroblast differentiation through TGF-β1/ERK axis in human cardiac fibroblasts. Eur J Pharmacol2023; 951: 175780.
26.
MoroniGTrendelenburgMDel PapaN, et al.Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis2001; 37: 490–498.
27.
CalatroniMMoroniGConteE, et al.Anti-C1q antibodies: a biomarker for diagnosis and management of lupus nephritis. A narrative review. Front Immunol2024; 15: 1410032.
28.
PangYTanYLiY, et al.Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. Kidney Int2016; 90: 1357–1367.
29.
CoremansIEMSpronkPEBootsmaH, et al.Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis1995; 26: 595–601.
30.
BaiYTongYLiuY, et al.Self-dsDNA in the pathogenesis of systemic lupus erythematosus. Clin Exp Immunol2018; 191: 1–10.
31.
MuñozLELauberKSchillerM, et al.The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol2010; 6: 280–289.
32.
RekvigOP. The dsDNA, anti-dsDNA antibody, and lupus nephritis: what we agree on, what must Be done, and what the best strategy forward could be. Front Immunol2019; 10: 1104.
33.
KrishnanMRWangCMarionTN. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int2012; 82: 184–192.
34.
RekvigOP. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. Clin Exp Immunol2015; 179: 5–10.
35.
MisraRGuptaR. Biomarkers in lupus nephritis. Int J Rheum Dis2015; 18: 219–232.
36.
SunXGanHXiaY. Changes of serum advanced glycation end products (AGEs), matrix metalloprotein-2 (MMP-2), and urinary microalbuminuria (mALB) in diabetic nephropathy and their predictive value for heart failure. Transl Androl Urol2021; 10: 1279–1285.
37.
MălăescuG-GMireaOCapotăR, et al.Left atrial strain determinants during the cardiac phases. JACC Cardiovasc Imaging2022; 15: 381–391.
38.
HuangSZhangZCuiY, et al.Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus. Clin Rheumatol2023; 42: 1565–1572.
39.
SzabóMZSzodorayPKissE. Dyslipidemia in systemic lupus erythematosus. Immunol Res2017; 65: 543–550.
40.
NishiHHigashiharaTInagiR. Lipotoxicity in kidney, heart, and skeletal muscle dysfunction. Nutrients2019; 11: 1664.
41.
HeWXiePLiW, et al.Impaired left ventricular systolic synchrony in patients with lupus Nephritis: a speckle tracking echocardiography study. Lupus2022; 31: 1084–1093.
42.
LiuYYinSLinZ, et al.Two-dimensional speckle-tracking echocardiography in left ventricular systolic function in patients with systemic lupus erythematosus. Clin Rheumatol2024; 43: 1871–1880.
ZhangHYangCGaoF, et al.Evaluation of left ventricular systolic function in patients with systemic lupus erythematosus using ultrasonic layer-specific strain technology and its association with cardiovascular events: a long-term follow-up study. Cardiovasc Ultrasound2022; 20: 25.
